Bimatoprost efficacy and safety as an initial hypotensive therapy in primary open-angle glaucoma
https://doi.org/10.25700/NJG.2019.01.05
Abstract
Purpose: To study the efficacy and safety of Bimoptic® (bimatoprost 0.03%, "Rompharm Company") as the initial monotherapy in early and advanced stages of primary open-angle glaucoma.
Methods: In 2018, clinics in 23 cities of Russia recruited 178 patients (294 eyes) with newly diagnosed primary open-angle glaucoma with uncompensated IOP (84 men, 94 women, average age - 64.3 years). The mild stage was diagnosed in 72, moderate - in 222 eyes. Tonometry was performed using a Maklakov 10 g tonometer. All patients after standard ophthalmologic examination were prescribed bimatoprost 0.03% 1 time per day. Tonometry was performed before the study, and on the months 1, 2, and 3.
Results: Initial IOP equaled 26.2+3.4 mmHg. On the month 1 IOP decreased by 25.6% to 19.5+2,5 mmHg (p<0.0001). On the month 2 IOP was 18,5 mmHg (29.4% decrease, p<0.0001), on the month 3 - 18.1 mmHg (31% decrease, p<0.0001).
On the month 1, IOP was compensated in 94% of all patients, on month 2 - in 98%, on month 3 - in 99% patients.
Bimatoprost was tolerated well. The most common adverse effect was conjunctival hyperemia (4.5% of all patients).
Conclusion: Bimatoprost allows compensating IOP as monotherapy in patients with early and advanced stages of primary open-angle glaucoma.
About the Authors
V. P. Erichev
Research Institute of Eye Diseases of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Med.Sc.D., Professor, Head of Glaucoma Department.
11 A,B Rossolimo St., Moscow, 119021
S. Yu. Petrov
Research Institute of Eye Diseases of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Med.Sc.D., Leading research associate.
11 A,B Rossolimo St., Moscow, 119021
I. V. Kozlova
Research Institute of Eye Diseases of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Ph.D., Senior research associate.
11 A,B Rossolimo St., Moscow, 119021
A. V. Volzhanin
Research Institute of Eye Diseases of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Postgraduate student.
11 A,B Rossolimo St., Moscow, 119021
Yu. K. Murakhovskaya
I.M. Sechenov First Moscow Medical University
Russian Federation
Russian Federation
Student.
8-2 Trubetskaya st., Moscow, 119991
References
1. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th edition. Savona: Italy PubliComm; 2014.
2. National Guidelines for Glaucoma: Manual for the doctors, 3rd ed. Edited by: Egorov E.A., Astakhov Yu.S., Erichev V.P. Moscow: GEOTAR-Media Publ.; 2015. 456 p. (In Russ).
3. Hylton C., Robin A.L. Update on prostaglandin analogs. Curr Opin Ophthalmol. 2003; 14(2):65-69.
4. Krauss A.H., Woodward D.F. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004; 49 Suppl 1:S5-11. doi: 10.1016/j.survophthal.2003.12.014.
5. Woodward D.F., Krauss A.H., Chen J., Lai R.K., Spada C.S., Burk R.M., Andrews S.W., Shi L., Liang Y., Kedzie K.M., Chen R., Gil D.W., Khar-lamb A., Archeampong A., Ling J., Madhu C., Ni J., Rix P., Usansky J., Usansky H., Weber A., Welty D., Yang W., Tang-Liu D.D., Garst M.E., Brar B., Wheeler L.A., Kaplan L.J. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001; 45 Suppl 4:S337-345.
6. Woodward D.F., Krauss A.H., Chen J., Liang Y., Li C., Protzman C.E., Bogardus A., Chen R., Kedzie K.M., Krauss H.A., Gil D.W., Kharlamb A., Wheeler L.A., Babusis D., Welty D., Tang-Liu D.D., Cherukury M., Andrews S.W., Burk R.M., Garst M.E. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003; 305(2):772-785. doi: 10.1124/jpet.102.047837.
7. Brubaker R.F., Schoff E.O., Nau C.B., Carpenter S.P., Chen K., Vanden-burgh A.M. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001; 131(1):19-24.
8. Richter M., Krauss A.H., Woodward D.F., Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prosta-mide. Invest Ophthalmol Vis Sci. 2003; 44(10):4419-4426.
9. Wan Z., Woodward D.F., Cornell C.L., Fliri H.G., Martos J.L., Pettit S.N., Wang J.W., Kharlamb A.B., Wheeler L.A., Garst M.E., Landsverk K.J., Struble C.S., Stamer W.D. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci. 2007; 48(9):4107-4115. doi: 10.1167/iovs.07-0080.
10. Davies S.S., Ju W.K., Neufeld A.H., Abran D., Chemtob S., Roberts L.J., 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003; 19(1):45-54. doi: 10.1089/ 108076803762718105.
11. Camras C.B., Toris C.B., Sjoquist B., Milleson M., Thorngren J.O., Hejkal T.W., Patel N., Barnett E.M., Smolyak R., Hasan S.F., Hellman C., Meza J.L., Wax M.B., Stjernschantz J. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004; 111(12):2193-2198. doi: 10.1016/j.ophtha.2004.06.028.
12. Maxey K.M., Johnson J.L., LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002; 47 Suppl 1:S34-40.
13. Hellberg M.R., Ke T.L., Haggard K., Klimko P.G., Dean T.R., Graff G. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. J Ocul Pharmacol Ther. 2003; 19(2):97-103. doi: 10.1089/108076803321637627.
14. Eisenberg D.L., Toris C.B., Camras C.B. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002; 47 Suppl 1:S105-115.
15. Gandolfi S.A., Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003; 110(3):609-614. doi: 10.1016/S0161-6420(02)01891-2.
16. Simmons S.T., Dirks M.S., Noecker R.J. Bimatoprost versus latano-prost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther. 2004; 21(4):247-262.
17. Eisenberg D. Latanoprost versus bimatoprost. Ophthalmology. 2003; 110(9):1861-1862; author reply 1862. doi: 10.1016/S0161-6420(03)00849-2.
18. Wang K., Xu L., Yuan Z., Yao K., Zhao J., Xu L., Fang A., Zhang M., Wu L., Ji J., Hou J., Liu Q., Sun X. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. BMC Ophthalmol. 2014; 14:21. doi:10.1186/1471-2415-14-21.
19. Day D.G., Walters T.R., Schwartz G.F., Mundorf T.K., Liu C., Schiff-man R.M., Bejanian M. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol. 2013; 97(8):989-993. doi: 10.1136/bjophthalmol-2012-303040.
20. Mishra D., Sinha B.P., Kumar M.S. Comparing the efficacy of latano-prost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma. Korean J Ophthalmol. 2014; 28(5):399-407. doi: 10.3341/kjo.2014.28.5.399.
21. Parrish R.K., Palmberg P., Sheu W.P., Group X.L.T.S. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135(5):688-703.
22. Berenson K.L., Kymes S., Hollander D.A., Fiscella R., Burk C., Patel V.D. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma. Am J Manag Care. 2011; 17(9):e365-374.
Review
For citations:
Erichev V.P., Petrov S.Yu., Kozlova I.V., Volzhanin A.V., Murakhovskaya Yu.K. Bimatoprost efficacy and safety as an initial hypotensive therapy in primary open-angle glaucoma. National Journal glaucoma. 2019;18(1):33-38. (In Russ.) https://doi.org/10.25700/NJG.2019.01.05
Views:
791
Email this article 